Anastasia V. Zimina
Omsk, OMS, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 31, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.
Journal: Current medical research and opinion
Published: June 18, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 15, 2025
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
Journal: Clinical lung cancer
Published: May 30, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.
Journal: Cancer communications (London, England)
Published: August 06, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: May 28, 2024
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT).
Journal: Frontiers in oncology
Published: February 13, 2024
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 17, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 28, 2023
Showing 1-10 of 10
Last Updated: 09/26/2026